Boston Scientific

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Boston Scientific (Booth 814) is highlighting various lectures, presentations and analyses of the recently released results of the SYNTAX trial.

The SYNTAX trial aims to explore the interface between treatment with CABG and PCI in patients with three-vessel and left main stem disease, comparing CABG using contemporary techniques and PCI using Boston Scientific’s Taxus drug eluting stents.

The majority of the lectures and presentations will take place on Tuesday, Oct, 14, when from 2:00-6:00, an entire session will be dedicated to the “Revascularization for Left Main and Triple Vessel Disease: Focus on SYNTAX” in room 147AB.